Tiotropium-olodaterol
Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity
... with tiotropium/olodaterol vs 1.875 L with tiotropium (difference: 115 mL; 95% CI: 77, 153; ...with tiotropium/olodaterol (all ...with tiotropium/ olodaterol in the ...
13
Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease
... received tiotropium/olodaterol, tiotro- pium, or ...doses, tiotropium/olodaterol 5/5 μg, tiotropium 5 μg, and olodaterol 5 ...with tiotropium/ olodaterol 5/5 μg in ...
11
<p>Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting</p>
... Overall, at Visit 2, the majority of patients were either “ very satis fi ed ” or “ satis fi ed ” with receiving tiotropium/ olodaterol treatment. Virtually identical results were observed with regard to ...
13
Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study
... The decision to treat was taken independently of participa- tion in the study and was made by the physician before the invitation to participate. Those eligible to participate were patients aged $40 years with a ...
8
<p>Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD</p>
... comparing tiotropium/olodaterol 5/5 µg with tiotropium and olodaterol monotherapies in patients par- ticipating in the TONADO ® studies showed that there were no dose- or time-related trends ...
10
<p>Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO<sup>®</sup> and OTEMTO<sup>®</sup> studies: a subgroup analysis by age</p>
... received tiotropium + olodaterol 2.5/5 μg or 5/5 μg, tiotropium 5 μg or ...only), olodaterol 5 μg (TONADO only), or placebo (OTEMTO ...of tiotropium + olodaterol 5/5 μg, ...
10
<p>Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients</p>
... Variables were collected at both Visit 1 (baseline) and Visit 2 (after approximately 6 weeks of treatment). The following variables were recorded: demographics; history of COPD, last record of spirometric COPD severity ...
12
<p>Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO<sup>®</sup> study</p>
... with tiotropium/ olodaterol combination therapy compared with tiotropium ...with tiotropium/olodaterol combination therapy in patients with less severe disease could contribute to ...
13
Long-term safety of tiotropium/olodaterol Respimat<sup>®</sup> in patients with moderate-to-very severe COPD and renal impairment in the TONADO<sup>®</sup> studies
... While olodaterol is mainly metabolized by the liver, and its metabolites excreted in the feces, tiotropium is primarily eliminated by the kidneys, and increasing plasma concentra- tions have been noted in ...
13
<p>No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD</p>
... assessing tiotropium/olodaterol 5/5 µg therapy versus tiotropium 5 µg or olodaterol 5 µg monotherapy, inhaled once daily (two single inhalations) using the Respimat ® Soft Mist ™ inhaler ...
9
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
... together tiotropium and olodaterol provide a powerful and persistent bronchodilation, responsible for an effective lung deflation which guarantees relevant therapeutic benefits with special regard to ...
10
UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
... of tiotropium + olodaterol FDC versus tiotropium, whereas this analysis compares other LAMA + LABA combinations with tiotropium + olodaterol ...to tiotropium + olodaterol ...
8
Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD
... FDC tiotropium and olodaterol compared with monotherapy (T/O 5/5 μ g, T 5 μ g; O 5 μ g; placebo), exercise capacity, and physical activity in addition to supervised exercise training and behavior modi- ...
11
Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective
... OLO: Olodaterol; PP: Per-protocol; PSA: Probabilistic sensitivity analyses; PTP: Price to public; QALYs: Quality-adjusted life years; SAL: Salbutamol; SE: Standard error; SGRQ-C: ...TIO: Tiotropium; UMEC: ...
13
Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
... Background: The DYNAGITO study was a Phase IIIb, randomized, double-blind, multicenter, active-controlled, parallel-group, 52-week study designed to determine the efficacy and safety [r] ...
10
The lung function profile of once-daily tiotropium and olodaterol via Respimat<sup>®</sup> is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler<sup>®</sup> (ENERGITO<sup>®</sup> study)<div><br /></div>
... of tiotropium + olodaterol over a period of 1 year, including FEV 1 area under the curve (AUC) from 0 hour to 3 hours (AUC 0–3 ) response, trough FEV 1 , and St George’s Respiratory Questionnaire ...
13
Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
... of tiotropium–olodaterol 5–5 µg once daily in adult patients with COPD was documented in eleven large, multicenter trials of up to 52 weeks ...duration. Tiotropium–olodaterol 5–5 µg not only ...
15
Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands
... This is the first full economic evaluation of tiotropium– olodaterol FDC for the Netherlands. It is based on the best currently available evidence, a validated model, and includes extensive uncertainty ...
11
<p>Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results</p>
... the tiotropium + olodaterol group compared with the tiotropium-only group was ...with tiotropium monotherapy, no changes were made to the model ...
10
The efficacy and safety of combined tiotropium and olodaterol via the Respimat<sup>®</sup> inhaler in patients with COPD: results from the Japanese sub-population of the Tonado<sup>®</sup> studies
... set). Tiotropium + olodaterol therapy was compared to the component monotherapies at 5% level of significance in which the mean changes from baseline in FEV 1 AUC 0–3 and trough FEV 1 and the mean SGRQ ...
11